20-F: CollPlant Biotechnologies Reports Annual Results, Highlights Progress in Regenerative Medicine

CollPlant Biotechnologies Ltd. releases its annual report for the year ended December 31, 2024, showcasing advancements in its rhCollagen-based regenerative and aesthetic medicine programs.

Summary

• CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, has released its annual report for the fiscal year ended December 31, 2024.
• The company is focused on medical aesthetics and 3D bioprinting of tissues and organs, utilizing its recombinant human collagen (rhCollagen) technology.
• A key development is the collaboration with AbbVie on dermal and soft tissue fillers, with a $2 million milestone payment received in February 2025, following a $10 million payment in June 2023.
• Clinical trials for the dermal filler product are ongoing, managed by AbbVie, with data collection and interim results under review.
• CollPlant is also developing 3D-bioprinted breast implants for tissue regeneration, targeting a $3 billion global market, with pre-clinical studies showing encouraging results.
• A photocurable regenerative dermal filler is in development, designed for skin lifting, rejuvenation, and facial contouring, with preclinical studies demonstrating superior tissue regeneration.
• The company commercially launched Collink.3D 50L in powder form in January 2023, expanding its bioink platform for 3D-bioprinting applications.
• The company's rhCollagen production process uses plant-based genetic engineering, promoting ethical and sustainable practices.
• CollPlant's ordinary shares are traded on the Nasdaq Global Market under the symbol CLGN.
• The company incurred a total comprehensive loss of $16.6 million for the year ended December 31, 2024 and a total comprehensive loss of $7.0 million for the year ended December 31, 2023.
• As of December 31, 2024, the company's cash and cash equivalents were $11.9 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the company's research and development programs, the significant net loss and the need for additional funding raise concerns about its financial stability. The sentiment is neutral, reflecting both the potential and the challenges facing the company.

Positives

• The collaboration with AbbVie continues to progress, with milestone payments indicating advancement in the dermal filler product development.
• Pre-clinical results for the 3D-bioprinted breast implants are promising, suggesting potential for a revolutionary alternative in aesthetic and reconstructive procedures.
• The launch of new bioink products expands CollPlant's market reach and addresses the growing demand for 3D-bioprinting solutions.
• The company is committed to environmental sustainability and responsible corporate governance, as demonstrated by its ESG report and membership in the UN Global Compact.

Negatives

• The company has a history of significant losses and anticipates continuing to incur losses for the foreseeable future.
• The company will need to raise additional funding, which may not be available on acceptable terms, or at all.
• The company depends heavily on the future success of its medical aesthetics and 3D-bioprinting product candidates.
• The company has low scale experience in producing its rhCollagen, and if it is unable to manufacture its rhCollagen in high commercial quantities successfully and consistently to meet demand, its growth will be limited.
• The company faces potential product liability, and, if successful claims are brought against it, it may incur substantial liability and costs.
• The company's business may be adversely affected if there is a resurgence of the COVID-19 pandemic.
• The company's business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.

Risks

• The company's future success depends on its ability to retain senior management, consultants, and advisors and to attract, retain, and motivate qualified personnel.
• The company's business and operations would suffer in the event of computer system failures or security breaches.
• The company's development and production of rhCollagen relies upon the continued availability of tobacco plants, and any interruption in availability or supply of tobacco plants may delay production and adversely affect commercial utilization of its rhCollagen-based products.
• The company may use its financial and human resources to pursue a particular research program or product and fail to capitalize on programs or products that may be more profitable or for which there is a greater likelihood of success.
• The market price of the company's ordinary shares may be highly volatile.
• Potential political, economic, and military instability in the State of Israel, where the majority of the company's senior management and its research and development facilities are located, may adversely impact its results of operations.

Future Outlook

The company expects to continue to incur expenses and operating losses for the foreseeable future, with the transition to profitability dependent on the successful development and commercialization of its products and product candidates.

Industry Context

The company operates in the regenerative and aesthetic medicine fields, which are rapidly changing. The company has competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies, medical technology companies, and universities and other research institutions.

Comparison to Industry Standards

• The company's regenerative breast implants aim to address an estimated $3.0 billion global breast implant market which is expected to reach $4.1 billion by 2033.
• The global advanced wound care market in terms of revenue was estimated to be worth $11.2 billion in 2022 and is poised to reach $17.7 billion by 2027, growing at a CAGR of 9.4% from 2022 to 2027, according to Markets And Markets.
• The global orthobiologics market size was valued at $8.36 billion in 2022 and is projected to grow $8.77 billion in 2023 to $12.78 billion by 2030, exhibiting a CAGR of 5.5% during 2023-2030, according to Fortune Business Insights.
• According to Allied Market Research report, titled, Dermal Filler Market, global dermal filler market size accounted over $6.3 billion in 2023 and is estimated to grow at 10.3% to reach $16.8 billion by 2033.
• Grand View Research Inc. estimates that the global 3D bioprinting market size was valued at $2.0 billion in 2022 and that the global market is expected to grow at a compound annual growth rate (CAGR) of 12.5% from 2023 to 2030.

Related Party Transactions

• The company has contracted CollPlant Ltd., the Company's wholly owned subsidiary, for its management and administrative services, for which CollPlant Ltd. pays the Company NIS 400,000 on a monthly basis.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity issuances.
• Employees may be affected by cost-cutting measures, including workforce reductions.
• Patients may benefit from the development of innovative regenerative medicine products.
• The company's suppliers and partners may be impacted by changes in its financial condition and business strategy.

Next Steps

• AbbVie will determine the next steps for the dermal filler program upon concluding their assessment of interim results from the first cohort of patients.
• The company plans to continue to optimize the regenerative breast implants to ensure longevity and re-modelling of the neo-tissue.
• The company is expecting to have initial results from the pre-clinical study with CollPlant's 200cc commercial-sized implants printed on Stratasys Origin 3D printer in the first half of 2025.

Key Dates

Keywords

rhCollagen, regenerative medicine, 3D bioprinting, medical aesthetics, dermal fillers, breast implants, bioinks, AbbVie, clinical trials, bioprinting